What REMS risk is associated with Saxenda?

Prepare for the CPJE Law Test. Explore flashcards and multiple choice questions with detailed explanations. Ace your exam with comprehensive prep!

Multiple Choice

What REMS risk is associated with Saxenda?

REMS risk centers on the most serious safety concerns that govern how a drug is prescribed and monitored. For Saxenda (liraglutide), the major safety signals are medullary thyroid carcinoma (MTC) and pancreatitis. In the labeling, MTC is highlighted with a boxed warning, and pancreatitis has been observed in patients taking GLP-1 receptor agonists like liraglutide, so clinicians monitor for sudden, persistent abdominal pain that could indicate pancreatitis and discontinue if suspected. Neutropenia, hypotension, and addiction are not the primary REMS-associated risks for this drug.

REMS risk centers on the most serious safety concerns that govern how a drug is prescribed and monitored. For Saxenda (liraglutide), the major safety signals are medullary thyroid carcinoma (MTC) and pancreatitis. In the labeling, MTC is highlighted with a boxed warning, and pancreatitis has been observed in patients taking GLP-1 receptor agonists like liraglutide, so clinicians monitor for sudden, persistent abdominal pain that could indicate pancreatitis and discontinue if suspected. Neutropenia, hypotension, and addiction are not the primary REMS-associated risks for this drug.

More practice questions